Study on the effect of quality of life with levetiracetam in the therapy for young epileptic patients

Abstract

Objective To evaluate the effect of quality of life (QOL) in the refractoriness young epileptic patients of partial seizures with the neotype antiepileptic drugs (AEDs) of levetiracetam. Methods All the patients were randomly divided into 2 groups, one was the treatment⁃group with the drug of levetiracetam, another was the control⁃group with the placebo to therapy. The effective power was compared after completed the 12 weeks therapy and evaluated the life quality of 2 groups with Quality of Life in Epilepsy Inventory⁃31 (QOLIE⁃31), respectively. Sequentially, all the patients were switched to the openness⁃therapy with 500 mg levetiracetam per day for 12 weeks, the life quality of all the patients were also estimated by the same QOLIE ⁃ 31 on the end of the therapy. Results The therapeutic effective power was obviously increased in the treatment⁃group (43.75% vs 35.72%, P = 0.031). The quality of life was significantly improved on the first end of 12 weeks treatment period with the treatment of levetiracetam (t = 3.905, P = 0.001), but the control⁃group did not increase their quality of life (t = 1.217, P = 0.245). The quality of life of patients in the 2 groups were significantly improved on the end of the 12 weeks for openness⁃therapy (t = 4.940, P=0.021; t = 2.575, P = 0.023). Conclusion Levetiracetam can treat the refractoriness young epileptic patients of partial seizures as an adjunctive treatment drug, it may significantly decrease the seizure frequency and it has advantage in improving the life quality of epileptic patients.

DOI：10.3969/j.issn.1672-6731.2010.06.011